Show simple item record

Files in this item

Thumbnail

Item metadata

dc.contributor.authorChu, Gavin C. W.
dc.contributor.authorLazare, Kim
dc.contributor.authorSullivan, Frank
dc.date.accessioned2018-02-14T10:30:07Z
dc.date.available2018-02-14T10:30:07Z
dc.date.issued2018-02-13
dc.identifier.citationChu , G C W , Lazare , K & Sullivan , F 2018 , ' Serum and blood based biomarkers for lung cancer screening : a systematic review ' , BMC Cancer , vol. 18 , 181 . https://doi.org/10.1186/s12885-018-4024-3en
dc.identifier.issn1471-2407
dc.identifier.otherPURE: 252130956
dc.identifier.otherPURE UUID: d05db45b-e972-485a-b610-493089ab6358
dc.identifier.otherScopus: 85042070858
dc.identifier.otherWOS: 000425516500006
dc.identifier.urihttp://hdl.handle.net/10023/12719
dc.description.abstractBackground Lung cancer is the second most common cancer and the leading cause of cancer death for both men and women. Although low-dose CT (LDCT) is recommended for lung cancer screening in high-risk populations and may decrease lung cancer mortality, there is a need to improve the accuracy of lung cancer screening to decrease over-diagnosis and morbidity. Blood and serum-based biomarkers, including EarlyCDT-lung and microRNA based biomarkers, are promising adjuncts to LDCT in lung cancer screening. We evaluated the diagnostic performance of EarlyCDT-lung, micro-RNA signature classifier (MSC), and miR-test, and their impact on lung cancer-related mortality and all-cause mortality. Methods References were identified using searches of PubMed, EMBASE, and Ovid Medline® from January 2000 to November 2015. Phase three or greater studies in the English language evaluating the diagnostic performance of EarlyCDT-lung, MSC, and miR-test were selected for inclusion. Results Three phase 3 studies were identified, one evaluating EarlyCDT-lung, one evaluating miR-Test, and one evaluating MSC respectively. No phase 4 or 5 studies were identified. All three biomarker assays show promise for the detection of lung cancer. MSC shows promise when used in conjunction with LDCT for lung cancer detection, achieving a positive likelihood ratio of 18.6 if both LDCT and MSC are positive, and a negative likelihood ratio of 0.03 if both LDCT and MSC are negative. However, there is a paucity of high-quality studies that can guide clinical implementation. Conclusion There is currently no high quality evidence to support or guide the implementation of these biomarkers in clinical practice. Reports of further research at stages four and five for these, and other promising methods, is required.
dc.format.extent6
dc.language.isoeng
dc.relation.ispartofBMC Canceren
dc.rights© The Author(s). 2018. Open Access. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.en
dc.subjectLung canceren
dc.subjectScreeningen
dc.subjectSystematic reviewen
dc.subjectBiomarkersen
dc.subjectPrimary health careen
dc.subjectRC0254 Neoplasms. Tumors. Oncology (including Cancer)en
dc.subject.lccRC0254en
dc.titleSerum and blood based biomarkers for lung cancer screening : a systematic reviewen
dc.typeJournal itemen
dc.description.versionPublisher PDFen
dc.contributor.institutionUniversity of St Andrews.School of Medicineen
dc.contributor.institutionUniversity of St Andrews.Population and Behavioural Science Divisionen
dc.identifier.doihttps://doi.org/10.1186/s12885-018-4024-3
dc.description.statusPeer revieweden


This item appears in the following Collection(s)

Show simple item record